🧬 biology

Correcting mutant CFTR with a stabilizing nanobody reveals a novel active conformation of the channel

This study demonstrates that delivering a stabilizing nanobody (T2a) via mRNA lipid nanoparticles corrects F508del-CFTR trafficking and reveals a novel, non-canonical open-channel conformation, offering a new therapeutic paradigm for cystic fibrosis and other protein misfolding diseases.

Original authors: Cédric Govaerts, Marie Overtus, James Charlick, Tihomir Rubil, Andrew Paige, Blaine Loughlin, Zachary Rich, Mayuree Rodrat, Zhengrong Yang, Anita Balázs, John Kappes, Marcus Mall, David Sheppard, John

Published 2026-07-29

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Cédric Govaerts, Marie Overtus, James Charlick, Tihomir Rubil, Andrew Paige, Blaine Loughlin, Zachary Rich, Mayuree Rodrat, Zhengrong Yang, Anita Balázs, John Kappes, Marcus Mall, David Sheppard, John Hunt

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine your body is a bustling city, and every cell is a building with a front door that controls what comes in and goes out. For most people, these doors work perfectly, letting water and salt flow freely to keep the city hydrated and clean. But for people with a genetic condition called Cystic Fibrosis (CF), the blueprints for these doors are slightly off. The doors get stuck in the factory, never making it to the front of the building, or they arrive but refuse to open. This causes a buildup of thick, sticky mucus that clogs the lungs and digestive system, turning a simple city into a traffic jam. Scientists have spent decades trying to fix these broken doors. They've developed "correctors" that help the doors get to the front, and "potentiators" that help them wiggle open. But even with these tools, the doors don't always work perfectly, and some people still struggle. The big question is: can we build a better tool to help these doors not just arrive, but stay open and functional?

This paper tells the story of a team of scientists who decided to try a new approach: using a tiny, custom-made "molecular helper" called a nanobody to stabilize the broken door. Think of a nanobody as a microscopic, super-precise clamp that latches onto a specific part of the door to keep it from falling apart. The researchers focused on a specific broken door (a mutant version of a protein called CFTR) that is unstable and falls apart easily. They used a delivery system made of tiny fat bubbles (lipid nanoparticles) to send instructions (mRNA) into the cells, telling them to build these nanobody clamps.

The results were surprisingly exciting. When the scientists combined their new nanobody helper with the existing, approved drug treatments, the broken doors didn't just show up; they thrived. The number of working doors on the cell surface increased dramatically, far more than if they had just used the drugs alone. It was like adding a specialized support beam to a wobbly doorframe; the door didn't just stand up, it became sturdy enough to handle the daily rush.

But the real magic happened when they looked at how the doors actually moved. Usually, for these doors to open, two specific parts of the protein (called NBD1 and NBD2) have to snap together like a handshake. The scientists expected that because their nanobody clamped onto one of these parts, it would stop the handshake and keep the door closed. Instead, they found something wild: the door was opening anyway! In fact, the nanobody seemed to unlock a secret, alternative way for the door to open.

Using a high-tech camera called a cryo-electron microscope, the team took 3D snapshots of the protein. They saw that while some doors were stuck in a closed, "V-shaped" position (which is normal), others had adopted a completely new shape. In this new shape, the part the nanobody was holding (NBD1) had let go of its usual spot and moved to a different location, like a worker stepping aside to let a new path form. This movement allowed the door to open and let salt and water pass through, even without the usual "handshake" between the two main parts.

The paper suggests that this new, alternative way of opening the door is a natural possibility for the protein, one that the nanobody helped reveal and stabilize. It's as if the door had a secret backdoor that no one knew about, and the nanobody was the key that unlocked it. While the scientists are careful to say this is a discovery of a new mechanism rather than a guaranteed cure for everyone yet, the findings offer a fresh, hopeful perspective. They show that by stabilizing the broken parts of the protein with a targeted helper, we might be able to rescue the function of these doors in ways we never imagined, potentially offering new hope for treating Cystic Fibrosis and other diseases caused by misfolded proteins.

Technical Summary: Correcting Mutant CFTR with a Stabilizing Nanobody Reveals a Novel Active Conformation

Problem Statement
Cystic Fibrosis (CF) is a protein trafficking disease primarily caused by the F508del mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) channel. This mutation destabilizes the Nucleotide-Binding Domain 1 (NBD1), leading to protein degradation and a lack of functional channels at the plasma membrane. While clinically approved correctors (elexacaftor, tezacaftor) and potentiators (ivacaftor) have improved outcomes, they often restore only 40–50% of wild-type activity and show variable efficacy among patients. Current modulators bind to transmembrane domains far from the F508 site, suggesting a need for therapies that directly stabilize the misfolded NBD1 domain to rescue protein maturation and function.

Methodology
The authors employed a multi-disciplinary approach combining mRNA delivery, electrophysiology, and structural biology:

mRNA-LNP Delivery: To deliver a stabilizing nanobody (T2a) intracellularly, the team encapsulated T2a-encoding mRNA into lipid nanoparticles (LNPs) formulated for lung delivery. This allowed for the expression of T2a within the cell during the CFTR folding process.
Cellular and Functional Assays: The efficacy of T2a, alone and in combination with the triple-combination therapy (ETI), was assessed in HEK293 and CF human bronchial epithelial (CFBE41o-) cells expressing F508del-CFTR. Maturation was measured via immunoblotting (Band C vs. Band B), plasma membrane expression via flow cytometry, and channel function via halide-sensitive YFP quenching and Ussing chamber short-circuit current ( $I_{sc}$ ) measurements.
Single-Channel Electrophysiology: Excised inside-out membrane patches from BHK cells expressing WT or F508del-CFTR were used to analyze gating kinetics. Experiments compared acute addition of purified T2a protein versus chronic exposure via T2a mRNA LNPs, utilizing high-resolution filtering to detect sub-conductance states (S-CS).
Cryo-Electron Microscopy (Cryo-EM): Cryo-EM structures of WT-CFTR were determined in the presence and absence of T2a. The study utilized advanced classification and 3D variability analysis to resolve distinct conformational states, including a novel complex where NBD1 is detached from the transmembrane domains (TMDs).

Key Results

Synergistic Rescue: While T2a alone had minimal effect on F508del-CFTR maturation, its combination with ETI resulted in a synergistic increase in mature, fully glycosylated CFTR (Band C) and plasma membrane expression, reaching levels comparable to wild-type CFTR.
Enhanced Channel Activity: Functional assays confirmed that the synergistic increase in protein expression translated to significantly higher chloride currents. In Ussing chamber experiments, the combination of T2a and correctors doubled the CFTR-mediated $I_{sc}$ compared to correctors alone.
Novel Gating Mechanisms: Single-channel recordings revealed that T2a binding sustains channel activity at 37°C, protecting F508del-CFTR from thermal deactivation. Notably, T2a promoted frequent transitions to sub-conductance states (S-CS) and full open states.
Structural Discovery: Cryo-EM analysis identified two distinct T2a-bound conformations:
1. Inverted V-Shaped (Inactive): A state where T2a binds NBD1, preventing NBD1-NBD2 dimerization and locking the channel in a closed, inactive state.
2. Novel Active Conformation: A state where NBD1 detaches from the intracellular loops of TMD1 and reorients to bind the C-terminal $\alpha$ -helix of the "Lasso" motif. In this state, the TMDs reorganize into a pore-like structure similar to the phosphorylated, ATP-bound active state, despite the absence of NBD1-NBD2 dimerization.
Intrinsic Dynamics: Control experiments on WT-CFTR without T2a revealed a sub-population of particles with undocked NBD1 and a similar pore-like TMD arrangement, suggesting that NBD1 detachment is an intrinsic feature of CFTR dynamics, not solely induced by the nanobody.

Significance and Claims
The paper establishes a new paradigm for correcting protein trafficking diseases by using targeted nanobodies as molecular chaperones to stabilize specific misfolded domains. The authors claim that:

Therapeutic Potential: Stabilizing NBD1 with T2a, particularly in combination with existing correctors, offers a robust strategy to treat CF and potentially other class II mutations where current pharmacological correction is partial or poorly tolerated.
Conformational Landscape: The study reveals a previously uncharacterized active conformation of CFTR where channel opening occurs without the canonical NBD1-NBD2 dimerization. This challenges the prevailing model that NBD dimerization is strictly required for pore formation.
Mechanistic Insight: The findings suggest that NBD1 detachment and re-docking to the Lasso motif is a conserved feature in ABCC family proteins (like MRP4) that facilitates TMD reorganization for function. This expands the understanding of ABC protein regulation and opens avenues for developing mutation-specific therapies based on stabilizing these alternative active states.

More like this